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OBJECTIVES This study assessed the time course of resolution of left atrial appendage (LAA) stunning after
catheter ablation of chronic atrial flutter (AFL).
BACKGROUND Although the presence of LAA stunning after ablation of chronic AFL calls for anticoagu-
lation in the post-cardioversion period, limited information has been obtained, particularly
regarding its duration.
METHODS Sixteen patients who underwent ablation of chronic, pure AFL were studied, only five of
whom had structural heart disease and one of whom had a reduced left ventricular ejection
fraction. The LAA emptying velocities (LAAEV) and left atrial spontaneous echo contrast
(SEC) were assessed using transesophageal echocardiography before, within 24 h after, one
week after, and two weeks after ablation.
RESULTS Within 24 h after ablation, the LAAEV decreased from 39  10 cm/s during AFL to 21 
10 cm/s during sinus rhythm (p 0.01), with eight patients (50%) having documented SEC.
After one week, the LAAEV increased (39  17 cm/s, p  0.01 vs. within 24 h) and SEC
resolved in five of eight patients. After two weeks, the increase in LAAEV persisted (54 
14 cm/s, p  0.01 vs. 1 week) and SEC was no longer present in any of the patients. The
numbers of patients with LAAEV 30 cm/s and absence of SEC were three within 24 h, 11
at one week, and 16 at two weeks after ablation.
CONCLUSIONS Patients with chronic, pure AFL and preserved left ventricular function who will undergo
catheter ablation may not require anticoagulation therapy for more than two weeks after the
procedure because of the presence of forceful mechanical LAA contractions and the absence
of SEC. (J Am Coll Cardiol 2003;41:2207–11) © 2003 by the American College of
Cardiology Foundation
Although anticoagulation at the time of cardioversion
should be considered for patients with atrial flutter (AFL) in
the same manner as anticoagulation for patients with atrial
fibrillation (AF) (1), whether anticoagulation is necessary
after AFL cardioversion is still a controversial issue in the
light of the absence of any controlled trial on the efficacy of
anticoagulation in the post-cardioversion period of AFL (2).
There is a solid reason, however, to consider anticoagulation
in the post-cardioversion period for patients with AFL.
Transient left atrial appendage (LAA) dysfunction after
electrical cardioversion of AF and AFL is known to occur
(i.e., LAA stunning) and is thought to be commonly
associated with thrombus formation and embolic stroke
(3,4). Moreover, LAA stunning also occurs after chronic
AFL cardioversion by catheter ablation (5,6).
At present, curative catheter ablation is fast becoming the
initial therapy for chronic AFL, emphasizing the need for
further information on LAA stunning and the duration of
anticoagulation therapy after cardioversion of chronic AFL
(2). So far, only one study has practically investigated the
return of depressed LAA function to normal values after
cardioversion in patients with AFL by using transesopha-
geal echocardiographic (TEE) examinations and has pro-
vided information on the required duration of anticoagula-
tion therapy in the post-cardioversion period (5). The study
had the intervening period between the examinations (in-
terval between 30 min and 3 weeks post-cardioversion),
which prevented determination of the exact time course for
recovery of LAA function.
The aims of the present study were to assess the time
course of resolution of LAA stunning after AFL cardiover-
sion by catheter ablation intimately and to gain insight into
the required duration of anticoagulation therapy in the
post-cardioversion period.
METHODS
Patient population. Nineteen consecutive patients with
chronic, typical AFL lasting more than one month, without
a history of AF (i.e., chronic, pure AFL), who were
undergoing catheter ablation were recruited. The patients
who did not maintain sinus rhythm (SR) before completion
of serial TEE studies or could not complete scheduled TEE
were excluded from the study. After giving written, in-
formed consent, all study patients underwent TEE, electro-
physiologic study, and catheter ablation. This study was
approved by our institutional review board.
Definition of atrial flutter. Typical AFL was considered
present if: 1) the surface electrocardiogram (ECG) demon-
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strated negative or positive flutter waves in the inferior limb
leads and lead V1, with a regular atrial rate; and 2) the
electrophysiologic study confirmed that the flutter reentrant
circuit involved a tricuspid valve annulus–inferior vena cava
orifice/eustachian ridge isthmus, based on the activation and
entrainment mapping technique (7). “Chronic AFL” was
defined as AFL documented repeatedly on a surface ECG
without evidence of intermittent SR at consecutive outpa-
tient visits before study inclusion. The total arrhythmia
duration was defined as the duration of the arrhythmia
starting from the first episode of documented AFL.
Ablation procedure. After completion of the electrophysi-
ologic study, anatomically guided linear ablation of the
isthmus was performed with a 4-mm tip ablation catheter.
Radiofrequency pulses were delivered with the temperature
preset to 60°C for 60 s. A line of sequential overlapping
lesions was created beginning at the tricuspid valve annulus,
with stepwise withdrawal of the catheter until the last lesion
was delivered at the inferior vena cava/eustachian ridge. The
procedural end point was the termination of AFL and
production of bi-directional conduction block through the
isthmus.
Echocardiographic examination. To assess serial changes
in LAA function, TEE was conducted the day before
ablation, within 24 h after (19  2 h [range 17 to 23]), one
week after, and two weeks after restoration of SR (Fig. 1).
Patients were mildly sedated, if necessary, with intravenous
hydroxyzine hydrochloride before TEE probe intubation.
Then, TEE was performed using a commercially available
ultrasound system (SSA-380A, Toshiba Inc., Tokyo, Japan)
equipped with a 5-MHz multiplane TEE probe.
After achieving adequate LAA imaging, the following
measurements were made: LAA emptying flow velocities
(LAAEV), spontaneous echo contrast (SEC), and throm-
bus in the left atrium (LA), including LAA. The peak
LAAEV during a cardiac cycle was measured by pulsed
Doppler echocardiography, positioning a sample volume at
the level of the orifice. The measurement was obtained as an
average of over five consecutive cardiac cycles. “Spontaneous
echo contrast” was defined as the presence of dynamic
intracavitary echoes with a characteristic swirling pattern
distinct from white-noise artifact. The degree of SEC was
graded as absent, mild, or severe (8,9). A thrombus was
identified as an echo-dense intracavitary mass distinct from
the underlying endocardium and not caused by pectinate
muscle (10).
Transthoracic echocardiography was also performed the
day before ablation to determine the LA, left ventricular
end-diastolic, and end-systolic diameters. Left ventricular
fractional shortening and left ventricular ejection fraction
(LVEF) were derived from these measurements (11). One
investigator who had no knowledge of the patients’ clinical
information analyzed all echocardiographic data.
Anticoagulation therapy. Before and after ablation, all
patients received anticoagulation therapy with warfarin,
targeting an international normalized ratio of 2.0 to 2.5.
After restoration of SR, anticoagulation was discontinued
when LAAEV 30 cm/s and the absence of SEC were
both confirmed, except in the case of demonstrable LA or
LAA thrombus.
Statistical analysis. Data are presented as the mean value
 SD and range or frequencies. The intergroup differences
for continuous echocardiographic variables were evaluated
by repeated measures of analysis of variance, applying the
post hoc Scheffe´ test. A value of p  0.05 was considered
statistically significant. Analyses were performed with SAS
statistical software (Stat View, version 5.0).
RESULTS
Patient characteristics. Although all patients were re-
stored to SR immediately after ablation, three were excluded
from the data analysis because of the development of AF,
pacemaker implantation due to recurrent symptomatic sinus
arrest lasting3.0 s, or an inability to consent to subsequent
TEE after ablation. Therefore, data from 16 patients were
included in the analysis. The clinical and echocardiographic
characteristics of these patients are summarized in Table 1.
Structural heart disease was present in five patients (31%),
one of whom had a reduced LVEF 40%. Eight patients
Abbreviations and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
ECG  electrocardiogram
LA  left atrium/atrial
LAA  left atrial appendage
LAAEV  left atrial appendage emptying velocity
LVEF  left ventricular ejection fraction
SEC  spontaneous echo contrast
SR  sinus rhythm
TEE  transesophageal echocardiography
Figure 1. Flow diagram of transesophageal echocardiography (TEE)
protocol. AFL  atrial flutter.
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(50%) did not have structural heart disease, hypertension, or
diabetes mellitus. No patient had a history of embolism.
Left atrial appendage function. A recent study demon-
strated that LAA function after AFL ablation may be
dependent on heart rate (12). In this study, there were no
significant differences in the sinus rate of the patients at each
TEE examination after ablation. Serial changes in LAAEV
and an example of serial changes in LAA pulsed Doppler
flow are shown in Figures 2 and 3, respectively. The
LAAEV decreased from 39  10 cm/s (range 21 to 56)
during AFL to 21  10 cm/s (range 8 to 40) during SR at
the time of first TEE after ablation (p  0.01). After one
week, the LAAEV increased to 39  17 cm/s (range 13 to
69; p 0.01 vs. within 24 h). After two weeks, the LAAEV
continued to increase to 54  14 cm/s (range 31 to 86; p 
0.01 vs. 1 week). Furthermore, the LAAEV at two weeks
after restoration of SR was greater than that during AFL (p
 0.01). Stunning of the LAA, which was defined as a
decrease in LAAEV from before to after cardioversion of at
least 20% (3), was observed in 12 patients (75%) within
24 h, in 5 patients (31%) at one week, and in no patients at
two weeks after ablation.
Discontinuation of anticoagulation therapy. The TEE
examination within 24 h after ablation demonstrated new or
increased SEC in eight patients (Fig. 4). Two weeks after
ablation, the SEC had disappeared and the LAAEV ex-
ceeded 30 cm/s in all of the patients (Table 2). The
cumulative number of patients who had discontinuation of
anticoagulation therapy was 3 (19%) within 24 h, 11 (69%)
at one week, and 16 (100%) at two weeks after ablation.
Neither LA nor LAA thrombus was detected in any of the
patients by serial TEE examinations.
Atrial arrhythmia recurrence and thromboembolic events.
During the follow-up period of at least six weeks, no patient
had evidence of either AFL recurrence or AF, except for one
patient who developed AF (mentioned in “Patient charac-
Table 1. Clinical and Transthoracic Echocardiographic
Characteristics in Study Patients (n  16)
Age (yrs) 64  7
Gender (male/female) 15/1
Flutter cycle length (ms) 233  23
Arrhythmia duration (months; range) 25  37 (2–134)
Underlying disease* (n)
Coronary artery disease 3
Valvular heart disease 1





Previous embolic history 0
Echocardiographic variables
LAD (mm; range) 44  6 (30–58)
LVEDD (mm; range) 48  6 (40–65)
LVFS (%; range) 30  8 (8–44)
LVEF (%; range) 59  13 (18–74)
*More than one per patient possible.
LAD  left atrial diameter; LVEDD  left ventricular end-diastolic diameter;
LVFS  left ventricular fractional shortenig; LVEF  left ventricular ejection
fraction.
Figure 2. Serial changes in left atrial appendage (LAA) emptying flow
velocities in patients with chronic atrial flutter before and after ablation.
*By repeated measures of analysis of variance. Vertical bars indicate the
mean value  SD.
Figure 3. The left atrial appendage flow velocities are shown during atrial
flutter (A) and sinus rhythm of 20 h (B), 1 week after ablation (C), and 2
weeks after ablation (D). Paper speed of 50 mm/s.
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teristics”). Similarly, there were no thromboembolic events
in any of the patients.
DISCUSSION
To avoid stroke subsequent to ablation of chronic AFL,
anticoagulation therapy should be maintained even after the
procedure, in the light of the presence of LAA stunning.
This study demonstrates that within two weeks after cath-
eter ablation of chronic, pure AFL, forceful mechanical
LAA contractions are restored, and anticoagulation could
thereby be discontinued safely if the patient remains in SR.
These findings suggest that patients with chronic, pure AFL
who undergo catheter ablation may not require anticoagu-
lation therapy for more than two weeks after the procedure.
We believe these findings provide important clinical infor-
mation on anticoagulation therapy.
Anticoagulation and cardioversion. Significant LAA
stunning could continue for at least 15 min (4), and LAA
thrombus formation could be led by LAA stunning
after AFL cardioversion (6). Recently, Gallagher et al. (13)
demonstrated that the incidence of embolism after
cardioversion of AFL is similar to that of cardioversion
of AF and is appreciable (0.72% vs. 0.46%) when the
duration of post-cardioversion anticoagulation is not
strictly structured. Therefore, it may be adequate that
anticoagulation is recommended for three to four weeks
before and after cardioversion of patients with chronic
AFL, as well as that of patients with chronic AF (1).
Nevertheless, Grimm et al. (3) hypothesized that the
duration of anticoagulation required after AFL cardiover-
sion is likely to be significantly shorter than that required for
AF, because the return of LAA function to normal values
after cardioversion may be more rapid in patients with AFL
than in those with AF. This hypothesis also prompted us to
perform this study.
Comparison with previous studies. To our knowledge,
there is only one study that practically investigated the
return of depressed LAA function to normal values after
cardioversion of patients with chronic AFL. Sparks et al. (5)
evaluated LAA function and SEC by TEE before, imme-
diately after, 30 min after, and three weeks after ablation of
chronic AFL in 15 patients. They demonstrated that
significant LAA stunning and developed SEC were present
until 30 min after ablation. After three weeks of sustained
SR, these findings improved, and anticoagulation with
warfarin could be discontinued. In this study, we evaluated
LAA stunning within 24 h (19  2 h) and one and two
weeks after ablation of chronic AFL. Our study lacks the
data obtained immediately after, 30 min after, and three
weeks after ablation. However, it seems that there are no
significant differences between the present study and the
study by Sparks et al. (5) with respect to the patient
population and the mode of cardioversion. We believe both
studies provide complementary information. Accordingly,
we hypothesize as follows: 1) significant LAA stunning that
occurs immediately after AFL ablation continues from
several hours to one week; and 2) forceful LAA contractions
resume within two weeks and may continue to improve for
three weeks.
Study limitations. Our study has several limitations. The
limited sample size may have excluded subgroups of patients
at a particularly high risk for the development of thrombo-
embolism in the post-cardioversion period. These patients
may have a more delayed recovery of LAA function.
Second, we enrolled only patients with pure AFL and
obtained echocardiographic data from patients who had
maintained SR after ablation. Nevertheless, we may have
missed episodes of intermittent AF because both types of
arrhythmias may confer similar symptoms and indeed many
episodes of AF are asymptomatic (14). Therefore, it is
conceivable that episodes of occult AF could contribute to
our results. Third, the criteria used to justify discontinuation
of anticoagulation in this study (LAAEV 30 cm/s and
absence of SEC) were based on well-accepted observations
that LAAEV 20 cm/s and SEC are independent risk
factors for thromboembolism (15,16), but these criteria refer
mainly to persistent AF (not to cardioversion or AFL).
Table 2. Serial Changes in Number of Patients With Certain
Transesophageal Echocardiographic Indexes
Before Within 24 h 1 Week 2 Weeks
LAAEV
20 cm/s 0 9 2 0
21–30 cm/s 2 4 3 0
31–40 cm/s 6 3 6 2
40 cm/s 8 0 5 14
SEC 1 (16%) 8 (50%) 3 (19%) 0
Mild 1 5 3 0
Severe 0 3 0 0
LAAEV  left atrial appendage emptying velocities; SEC  spontaneous echo
contrast.
Figure 4. The spontaneous echo contrast (SEC) grade before and after
atrial flutter ablation.
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With respect to LAAEV, we had some safety margin to
LAAEV 20 cm/s in this study.
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